Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian; Tapan Kadia; Courtney DiNardo; Naval Daver; Gautam Borthakur; Elias Jabbour; Guillermo Garcia-Manero; Marina Konopleva; Farhad Ravandi

doi:10.1038/s41408-021-00425-3

Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian, Tapan Kadia, Courtney DiNardo, Naval Daver, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi

Leukemia

Research output: Contribution to journal › Review article › peer-review

296 Scopus citations

Abstract

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.

Original language	English (US)
Article number	41
Journal	Blood cancer journal
Volume	11
Issue number	2
DOIs	https://doi.org/10.1038/s41408-021-00425-3
State	Published - Feb 2021

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-021-00425-3

Cite this

@article{0abb90bebb4b47d6abfd7b2603a1f865,

title = "Acute myeloid leukemia: current progress and future directions",

abstract = "Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.",

author = "Hagop Kantarjian and Tapan Kadia and Courtney DiNardo and Naval Daver and Gautam Borthakur and Elias Jabbour and Guillermo Garcia-Manero and Marina Konopleva and Farhad Ravandi",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = feb,

doi = "10.1038/s41408-021-00425-3",

language = "English (US)",

volume = "11",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Acute myeloid leukemia

T2 - current progress and future directions

AU - Kantarjian, Hagop

AU - Kadia, Tapan

AU - DiNardo, Courtney

AU - Daver, Naval

AU - Borthakur, Gautam

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - Konopleva, Marina

AU - Ravandi, Farhad

PY - 2021/2

Y1 - 2021/2

N2 - Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.

AB - Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.

UR - http://www.scopus.com/inward/record.url?scp=85101404837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101404837&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00425-3

DO - 10.1038/s41408-021-00425-3

M3 - Review article

C2 - 33619261

AN - SCOPUS:85101404837

SN - 2044-5385

VL - 11

JO - Blood cancer journal

JF - Blood cancer journal

IS - 2

M1 - 41

ER -

Acute myeloid leukemia: current progress and future directions

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this